Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial. Methods: A systematic review and meta-analysis comparing PD-(L)1 and VEGF(R) blockade combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Qiyu, Wu, Dawei, Huang, Huiyao, Fang, Hong, Wu, Ying, Liu, Funan, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166877/
https://www.ncbi.nlm.nih.gov/pubmed/37180706
http://dx.doi.org/10.3389/fphar.2023.1093194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166877/
https://www.ncbi.nlm.nih.gov/pubmed/37180706
http://dx.doi.org/10.3389/fphar.2023.1093194

Ejemplares similares